Samuel George A. III 4
4 · Lineage Cell Therapeutics, Inc. · Filed Feb 12, 2024
Insider Transaction Report
Form 4
Samuel George A. III
General Counsel and Secretary
Transactions
- Exercise/Conversion
Common Shares, no par value
2024-02-11+6,076→ 9,674 total - Tax Payment
Common Shares, no par value
2024-02-11$1.08/sh−2,490$2,689→ 7,184 total - Exercise/Conversion
Restricted Stock Units
2024-02-11−6,076→ 12,151 totalExercise: $0.00→ Common Shares (6,076 underlying)
Footnotes (4)
- [F1]Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis.
- [F2]Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options.
- [F3]Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.
- [F4]The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026.